EWL holdings

Computed by this site from the fund's SEC Form N-PORT filing; what the measure does not tell you · every fund in one table · hold it with other funds? X-ray the mix. Pricing: 1.61% at a quoted market price (level 1), 4 issuer countries.

EWL's largest investment is Roche Holding AG at 14.03% of net assets. Novartis AG and Nestle SA follow; the three together are 39.93%. Ten companies are 68.01% of the fund; the other 35 share the rest. Among the 721 equity funds measured here, EWL behaves like 14.1 holdings against a median of 42.4 — 3.0 times more concentrated than the median. Across 27 quarterly filings EWL has held roughly steady since 2019-11-30 (11.9 then, 14.1 now). Between the 2026-02-28 and 2026-05-31 filings 3 positions were added and 2 dropped; 18.1% of the weight moved.

Each sentence is read from the fund's own SEC filing; the class median is computed across the comparable equity funds on this site. Nothing here is a view on the fund.

Between 2019-11-30 and 2026-05-31, EWL went from behaving like 11.9 equally weighted positions to 14.1 — 19% more, while its top ten went from 67.68% to 68.01% of net assets. Read across the funds on the concentration-over-time table.

One row per filed reporting period, newest first, read from EDGAR. Quarterly because that is the public filing cadence. Rows marked * are published but held out of the comparison above; the methodology page says when and why.

The 15 largest of 45 positions in EWL's Form N-PORT, weight as a share of net assets, securities-lending collateral excluded. Every position, every quarter: EWL.csv.gz.

Share of EWL's own investments by the issuer country the filer reported (incorporation, not revenue). Each country links to every fund that holds it.

Monthly total returns from Item B.5 of EWL's own filings, 81 months on record. Not computed here and not from a price feed.

Cross-checked against a series computed separately from prices: median difference 0.17 percentage points over 81 months, which is roughly the distributions. Every month with the filing it came from: EWL.json · all funds.

The fund lends its holdings, and Item B.4.a of the filing names every firm holding them. At 2026-05-31, $160,256 was out to 1 borrower, 0.01% of net assets.

Cash collateral reported against the loan: 0.01% of net assets, 106.4% of the amount lent. That is a floor on the collateral, not the whole of it — collateral the fund does not hold as a position is not in this filing, so a figure under 100% is not evidence of under-collateralisation. How that figure behaves across all funds. Every quarter EWL has filed, with each borrower: EWL.json · all funds.

44 positions became 45: 3 added (14.3% of the fund at the later date), 2 dropped (15.1% at the earlier date). Half the sum of all weight changes, a turnover proxy: 18.1%. Positions are matched on identifiers, so a security whose identifier changed shows as one drop and one add. Every filing of EWL compared this way, as a feed: changes.xml · all funds: filings received.

New: Roche Holding AG (14.24%), SWISS MKT IX FUTR JUN26 (0.05%), EURO STOXX 50 JUN26 (0.02%). Gone: Roche Holding AG (14.98%), SWISS MKT IX FUTR MAR26 (0.13%).

1.6% of EWL is carried at a quoted market price (fair-value level 1). Categories and levels are the filer's, from Form N-PORT; what a low level-1 share does and does not mean is in the measure's page.

A position count cannot describe a fund that uses derivatives, because a swap is filed at its unrealised gain, not its exposure. These are the notionals the fund itself reported, against net assets of $1.70B. Notional of an interest-rate or currency swap is not equity exposure.

Full detail for every fund that files derivatives: leverage.json (CC BY 4.0).

Every measured equity fund lined up by how many holdings it behaves like; these sit either side of EWL (14.1). Same filings, same arithmetic. Position in this list says nothing about which fund is better.